External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

World Journal of Urology

Volumn 29, Issue 4, 2011, Pages 409-414

  Hernández, Virginia ^a   de la Pena E ^a   Martin, M D ^a   Blazquez C ^a   Diaz, F J ^a   Llorente, C ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Bladder cancer; Prognostic factors; Progression; Recurrence

Indexed keywords

AGED; ARTICLE; BIOLOGICAL MODEL; BLADDER TUMOR; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MALE; METHODOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL MODEL; TUMOR RECURRENCE; VALIDATION STUDY;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 79960698217     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0635-2     Document Type: Article

References (21)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3): 466-477.
2. Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R (1995) Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 27(2): 110-116.
3. Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, De Pauw M, Sylvester R, Cheuvart B (1992) Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J Urol 148(2 Pt 1): 297-301.
4. Kurth K, Tunn U, Ay R, Schroder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R (1997) Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158(2): 378-384.
5. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153(3 Pt 2): 934-941.
6. Witjes JA, v d Meijden AP, Collette L, Sylvester R, Debruyne FM, van Aubel A, Witjes WP (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52(3): 403-410.
7. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149(4): 749-752.
8. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27(3): 295-300.
9. Donat SM, North A, Dalbagni G, Herr HW (2004) Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0. 5 cm. J Urol 171(2 Pt 1): 636-639.
10. Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6): 1216-1223.
11. Hernandez V, Alvarez M, de la Pena E, Amaruch N, Martin MD, de la Morena JM, Gomez V, Llorente C (2009) Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology 73(6): 1306-1310.
12. Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170(2 Pt 1): 438-441.
13. Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27(3): 289-293.
14. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46(17): 3040-3052. doi: S0959-8049(10)00878-6.
15. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F (2010) Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 21(6): 1323-1360.
16. Samanic C, Kogevinas M, Dosemeci M, Malats N, Real FX, Garcia-Closas M, Serra C, Carrato A, Garcia-Closas R, Sala M, Lloreta J, Tardon A, Rothman N, Silverman DT (2006) Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 15(7): 1348-1354.
17. Zaak D, Burger M, Otto W, Bastian PJ, Denzinger S, Stief CG, Buchner H, Hartmann A, Wieland WF, Shariat SF, Fritsche HM (2010) Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int 106(3): 342-348.
18. Saika T, Tsushima T, Nasu Y, Miyaji Y, Saegusa M, Takeda K, Kumon H (2010) Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study. World J Urol 28(4): 413-418.
19. Chiong E, Esuvaranathan K (2010) New therapies for non-muscle-invasive bladder cancer. World J Urol 28(1): 71-78.
20. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1): 680-684.
21. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182(5): 2195-2203.